Assessment of Factors Associated With Community-Acquired Extended-Spectrum β-Lactamase-Producing Escherichia coli Urinary Tract Infections in France. 2022

Adeline Paumier, and Antoine Asquier-Khati, and Sonia Thibaut, and Thomas Coeffic, and Olivier Lemenand, and Stéphanie Larramendy, and Brice Leclère, and Jocelyne Caillon, and David Boutoille, and Gabriel Birgand, and
Centre d'Appui à la Prévention des Infections Associées aux Soins des Pays de la Loire, Centre Hospitalier Universitaire (CHU)-Le Tourville, Nantes, France.

Extended-spectrum β-lactamase (ESBL)-producing Escherichia coli is considered a leading pathogen contributing to the global burden of antimicrobial resistance. To better understand factors associated with the heterogeneity of community-acquired ESBL-producing E coli urinary tract infections (UTIs) in France. This cross-sectional study performed from January 1 to December 31, 2021, was based on data collected via PRIMO (Surveillance and Prevention of Antimicrobial Resistance in Primary Care and Nursing Homes), a nationwide clinical laboratory surveillance system in France. Strains of E coli isolated from community urine samples from January 1 to December 31, 2019, from 59 administrative departments of metropolitan France were included. Quasi-Poisson regression models were used to assess the associations between several ecological factors available on government and administration websites between 2010 and 2020 (demographic population structure, living conditions, baseline health care services, antibiotic consumptions, economic indicators, animal farming density, and environmental characteristics) and the number of ESBL-producing E coli strains isolated from urine samples of individuals with community-acquired UTI in 2019. Among 444 281 E coli isolates from urine samples tested in 1013 laboratories, the mean prevalence of ESBL-producing E coli was 3.0% (range, 1.4%-8.8%). In an adjusted model, the number of community-acquired ESBL-producing E coli UTIs in each department was positively associated with the percentage of children younger than 5 years (adjusted β1 coefficient, 0.112 [95% CI, 0.040-0.185]; P = .004), overcrowded households (adjusted β1 coefficient, 0.049 [95% CI, 0.034 to 0.062]; P < .001), consumption of fluoroquinolones (adjusted β1 coefficient, 0.002 [95% CI, 0.001-0.002]; P < .001), and tetracyclines (adjusted β1 coefficient, 0.0002 [0.00004 to 0.00039]; P = .02), and poultry density (adjusted β1 coefficient, 0.0001 [95% CI, 0.0001-0.0002]; P < .001). The social deprivation index (adjusted β1 coefficient, -0.115 [95% CI, -0.165 to -0.064]; P < .001) and the proportion of water surface area (adjusted β1 coefficient, -0.052 [-0.081 to -0.024]; P = .001) were negatively associated with a higher number of community-acquired ESBL-producing E coli UTIs. The findings of this cross-sectional study suggest that multiple human health, animal health, and environmental factors are associated with the occurence of community-acquired ESBL E coli UTI. Strategies to mitigate ESBL in the community should follow the One Health approach and address the role played by fluoroquinolones, tetracycline use, poultry density, overcrowded households, and preschool-aged children.

UI MeSH Term Description Entries
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D004926 Escherichia coli A species of gram-negative, facultatively anaerobic, rod-shaped bacteria (GRAM-NEGATIVE FACULTATIVELY ANAEROBIC RODS) commonly found in the lower part of the intestine of warm-blooded animals. It is usually nonpathogenic, but some strains are known to produce DIARRHEA and pyogenic infections. Pathogenic strains (virotypes) are classified by their specific pathogenic mechanisms such as toxins (ENTEROTOXIGENIC ESCHERICHIA COLI), etc. Alkalescens-Dispar Group,Bacillus coli,Bacterium coli,Bacterium coli commune,Diffusely Adherent Escherichia coli,E coli,EAggEC,Enteroaggregative Escherichia coli,Enterococcus coli,Diffusely Adherent E. coli,Enteroaggregative E. coli,Enteroinvasive E. coli,Enteroinvasive Escherichia coli
D004927 Escherichia coli Infections Infections with bacteria of the species ESCHERICHIA COLI. E coli Infections,E. coli Infection,Infections, E coli,Infections, Escherichia coli,E coli Infection,E. coli Infections,Escherichia coli Infection,Infection, E coli,Infection, E. coli,Infection, Escherichia coli
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001618 beta-Lactamases Enzymes found in many bacteria which catalyze the hydrolysis of the amide bond in the beta-lactam ring. Well known antibiotics destroyed by these enzymes are penicillins and cephalosporins. beta-Lactamase,beta Lactamase,beta Lactamases
D013752 Tetracycline A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis. 4-Epitetracycline,Achromycin,Achromycin V,Hostacyclin,Sustamycin,Tetrabid,Tetracycline Hydrochloride,Tetracycline Monohydrochloride,Topicycline,4 Epitetracycline

Related Publications

Adeline Paumier, and Antoine Asquier-Khati, and Sonia Thibaut, and Thomas Coeffic, and Olivier Lemenand, and Stéphanie Larramendy, and Brice Leclère, and Jocelyne Caillon, and David Boutoille, and Gabriel Birgand, and
June 2013, Microbial drug resistance (Larchmont, N.Y.),
Adeline Paumier, and Antoine Asquier-Khati, and Sonia Thibaut, and Thomas Coeffic, and Olivier Lemenand, and Stéphanie Larramendy, and Brice Leclère, and Jocelyne Caillon, and David Boutoille, and Gabriel Birgand, and
May 2020, Medecine et maladies infectieuses,
Adeline Paumier, and Antoine Asquier-Khati, and Sonia Thibaut, and Thomas Coeffic, and Olivier Lemenand, and Stéphanie Larramendy, and Brice Leclère, and Jocelyne Caillon, and David Boutoille, and Gabriel Birgand, and
August 2019, Turkish journal of medical sciences,
Adeline Paumier, and Antoine Asquier-Khati, and Sonia Thibaut, and Thomas Coeffic, and Olivier Lemenand, and Stéphanie Larramendy, and Brice Leclère, and Jocelyne Caillon, and David Boutoille, and Gabriel Birgand, and
March 2016, The Southeast Asian journal of tropical medicine and public health,
Adeline Paumier, and Antoine Asquier-Khati, and Sonia Thibaut, and Thomas Coeffic, and Olivier Lemenand, and Stéphanie Larramendy, and Brice Leclère, and Jocelyne Caillon, and David Boutoille, and Gabriel Birgand, and
November 2021, Journal of clinical medicine,
Adeline Paumier, and Antoine Asquier-Khati, and Sonia Thibaut, and Thomas Coeffic, and Olivier Lemenand, and Stéphanie Larramendy, and Brice Leclère, and Jocelyne Caillon, and David Boutoille, and Gabriel Birgand, and
September 2014, Pediatric nephrology (Berlin, Germany),
Adeline Paumier, and Antoine Asquier-Khati, and Sonia Thibaut, and Thomas Coeffic, and Olivier Lemenand, and Stéphanie Larramendy, and Brice Leclère, and Jocelyne Caillon, and David Boutoille, and Gabriel Birgand, and
May 2021, Pediatrics and neonatology,
Adeline Paumier, and Antoine Asquier-Khati, and Sonia Thibaut, and Thomas Coeffic, and Olivier Lemenand, and Stéphanie Larramendy, and Brice Leclère, and Jocelyne Caillon, and David Boutoille, and Gabriel Birgand, and
November 2016, Enfermedades infecciosas y microbiologia clinica,
Adeline Paumier, and Antoine Asquier-Khati, and Sonia Thibaut, and Thomas Coeffic, and Olivier Lemenand, and Stéphanie Larramendy, and Brice Leclère, and Jocelyne Caillon, and David Boutoille, and Gabriel Birgand, and
February 2016, The Journal of infection,
Adeline Paumier, and Antoine Asquier-Khati, and Sonia Thibaut, and Thomas Coeffic, and Olivier Lemenand, and Stéphanie Larramendy, and Brice Leclère, and Jocelyne Caillon, and David Boutoille, and Gabriel Birgand, and
January 2019, Infectious diseases (London, England),
Copied contents to your clipboard!